Are Medical Stocks Lagging atai Life Sciences (ATAI) This Year?
Here is how atai Life Sciences N.V. (ATAI) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.
Psychedelics regain momentum in 2025 on political tailwinds, clinical wins
The psychedelics sector is experiencing a resurgence of optimism in 2025 driven by a more favorable federal government under President Donald Trump's administration, shifting state-level policies, and encouraging clinical trial results supporting the efficacy of psychedelic therapies. A major setback for the sector was the Food and Drug Administration rejecting Lykos Therapeutics' MDMA-assisted therapy for post-traumatic stress disorder in August last year.
FDA seen likely to grant emergency use authorizations for psychedelics, boosting sector stocks
The Food and Drug Administration (FDA) may soon issue emergency use authorizations for psychedelic substances like psilocybin, proponents of psychedelic therapy believe, amid a shit in attitude towards psychedelic therapies under the Trump administration. Emergency use authorizations (EUAs) are considered a more likely near-term regulatory pathway for psychedelics such as psilocybin because, unlike full FDA approval, they require a lower standard of evidence, a report from health-oriented news website Stat published on Wednesday highlighted.
Are You Looking for a Top Momentum Pick? Why atai Life Sciences N.V.
Does atai Life Sciences N.V. (ATAI) have what it takes to be a top stock pick for momentum investors?
Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year?
Here is how atai Life Sciences N.V. (ATAI) and Novartis (NVS) have performed compared to their sector so far this year.
atai Life Sciences gains maximum exposure to key psychedelic asset with Beckley Psytech merger
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) stock is poised to move higher following its planned merger with Beckley Psytech, as the combined entity will provide investors with maximum exposure to a promising therapy targeting treatment-resistant depression (TRD), analysts at Jefferies believe. BPL-003, Beckley's intranasal formulation of 5-MeO-DMT, is a short-acting psychedelic with the potential to deliver rapid and durable effects in TRD.
atai Life Sciences and Beckley Psytech to merge in all-share deal, stock pops
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) shares soared before Monday's opening bell after it announced it has inked a definitive agreement to merge with Beckley Psytech, a private clinical-stage biopharmaceutical company developing psychedelic-based therapies, in an all-share transaction valued at $390 million. The merger is contingent upon the achievement of pre-agreed success criteria in Beckley's ongoing Phase 2b trial of BPL-003 (mebufotenin benzoate), the company said.
atai Life Sciences expects key trial data by mid-2025 - ICYMI
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO and co-founder Dr Srinivas Rao talked with Proactive about the company's clinical development progress in 2025, highlighting multiple upcoming trial readouts. Proactive: Hello, you're watching Proactive.
atai Life Sciences N.V. (ATAI) Is Up 18.71% in One Week: What You Should Know
Does atai Life Sciences N.V. (ATAI) have what it takes to be a top stock pick for momentum investors?
atai Life Sciences N.V. (ATAI) Just Flashed Golden Cross Signal: Do You Buy?
Atai Life Sciences N.V. (ATAI) reached a significant support level, and could be a good pick for investors from a technical perspective.
Is atai Life Sciences (ATAI) Outperforming Other Medical Stocks This Year?
Here is how atai Life Sciences N.V. (ATAI) and Cardinal Health (CAH) have performed compared to their sector so far this year.
atai Life Sciences upside highlighted by analysts as more positive data backs Beckley Psytech's depression therapy
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) could see its stock more than double following the release of key trial data later in 2025, according to Jefferies analysts, following another batch of positive clinical trial results from Beckley Psytech's BPL-003 program targeting treatment-resistant depression (TRD). Beckley Psytech's Phase 2a study of BPL-003, an intranasal form of 5-MeO-DMT, showed that a single dose of the therapy along with selective serotonin reuptake inhibitor (SSRI) therapies, produced rapid, robust, and sustained antidepressant effects.
